Laurus Labs concludes USFDA inspection for API Facility with zero observations

20 May 2017 Evaluate

Laurus Labs has successfully completed the United States Food and Drug Administration (USFDA) inspection for its API facility of the Unit 2 without any Form 483 observations. The formulations unit in the same facility has however received Establishment Inspection Report (EIR) on May 18, 2017. The Unit-2 that manufactures active pharmaceutical ingredients and finished dosage formulations is located in APSEZ at Achutapuram, Vizag.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.


Laurus Labs Share Price

418.80 -8.30 (-1.94%)
31-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1462.50
Dr. Reddys Lab 5784.50
Cipla 1451.25
Zydus Lifesciences 1001.15
Lupin 1587.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.